Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2020 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
November 05, 2020 09:29 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Third Quarter Financial Results

BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
October 26, 2020 08:26 ET | Source: Cyclacel

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
October 23, 2020 16:30 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
October 05, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present at the October 2020 Lytham Partners Virtual Investor Growth Conference

BERKELEY HEIGHTS, N.J., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
September 21, 2020 07:00 ET | Source: Cyclacel

Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation in the Late Breaking and Best Proffered Paper Session at the 32nd EORTC-NCI-AACR Symposium 2020

BERKELEY HEIGHTS, N.J., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
August 12, 2020 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
August 05, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
July 13, 2020 07:00 ET | Source: Cyclacel

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
May 12, 2020 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel...